Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

S. Korea Approves Green Cross Vaccine Against H1N1 Flu

This article was originally published in PharmAsia News

Executive Summary

South Korean regulators gave their approval to the first Korean-produced vaccine against the H1N1 influenza virus, by Green Cross

South Korean regulators gave their approval to the first Korean-produced vaccine against the H1N1 influenza virus, by Green Cross.

The company's Green Flu-S was cleared by the Korean FDA for use in a single dose. Only seven other H1N1 vaccines have been approved by governments around the world. South Korea has planned to vaccinate 35 percent of the nation's population of 49 million people against the disease. (Click here for more)

"S. Korea Government Oks Sale Of Locally Produced Flu Vaccine" - Yonhap News Agency (S. Korea) (10/21/09)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC070149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By